ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG VÀ TÌNH HÌNH SỬ DỤNG THUỐC KHÁNG ĐÔNG TRÊN BỆNH NHÂN COVID-19 MỨC ĐỘ VỪA VÀ NẶNG TẠI KHOA ĐIỀU TRỊ 1 TRONG THÁNG 11

Tịnh Lê; Ân Vũ Đình; Cường Nguyễn Ngọc; Tuấn Hoàng Văn; Lợi Lê Văn

doi:10.59354/ydth175.2023.229

Keywords:

COVID-19, SARS-CoV-2

Abstract

Objective: To evaluate the clinical characteristics and laboratory fingdings, treatment patterns, focusing on the use of anticoagulants and their complications.

Matherial and Method: A retrospective cross-sectional study with analysis of 223 patients with confirmed moderate and severe Covid-19 treated at Treatment 1 Department, from November 1, 2021 to November 30, 2021. Results: 75.78% of COVID-19 patients have been Covid vaccinated, the majority of patients (85.2%) had comorbidities. Desarturation (100%) moderate Covid-19 group ( SpO2: 94.84 ± 6.46, severe Covid-19 group ( SpO2: 89.14 ± 2.10),, dyspnea (84,91%), cough (73,70%), were the most commonly recorded clinical symptoms. There was an increase in serum Ferritin, D-Dimer, PCT, CRP, white blood cell count, neutrophil count, and lymphocyte count at the time of admission. 90.13% of moderate and severe covid patients received anticoagulants during treatment, enoxaparin was the most used drug (82.22%) with prophylactic dose being the first priority dose (52.71%). The rate of bleeding when using anticoagulants was 3.14%.

Conclusion: The majority of demised COVID-19 patients in 175 Military Hospital had comorbilities and were Covid vaccinanted. Clinical and paraclinical characteristics between the two study groups were largely not statistically different, desarturation symptom were more severe in severe Covid-19 group than in moderate Covid-19 group. Low molecular weight heparin (LMWH) are used more often than unfractionated heparin (UFH). Bleeding complications due to anticoagulants are uncommon.

References

F. A. K. e. al, (2020) "Thrombosis Research," Inciden of thrombotic complication in critically ill ICU patients with COVID 19, pp. 35-40.

S. C. F. W. Songping Cui, (2020). "Journal of Thrombosis and Haemostasis," Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia, pp. 10-20.

B. Z. e. al, (2020). "Plos one," Clinical characteristics of 82 cases of death from COVID-19, p. 15.

W.-h. L. Wei-jie Guan, (2020). "The European Respiratory Journal," Comorbidity and its impact on 1590 patients with COVID-19 in China, p. 55.

M. C. W. M. Bin Cao, (2020). "The New England Journal of Medicine," A trial of Lopinavir- Ritonavir in Adults Hospitalized with Severe Covid-19, pp. 1787-1799.

M. M. Q. M. Shaobo Shi, (2020) "JAMA Cardiology," Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China, pp. 802-810.

F. Z. L. Zhang, (2020) "Annals of Oncology," Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China., pp. 894-901.

M. Arentz, (2020). "JAMA," Characteristics and Outcomes of 21 Critically ill Patients With COVID-19 in Washington State, pp. 1612-1614.

L. L. Lo, (2020) "International Journal of Biological Sciences," Evaluation of SARS-COV-2 RNA shedding in clinical spencimens and clinical characteristics of 10 patients with COVID-19 in Macau, pp. 1698-1707.

M. Sholzberg, (2021). "British medical journal," Effectiveness of therapeutic heparin versus prophylactic heparin on death, medical ventilation, or intensive care unit admission in moderately ill patients with covide-19 admitted to hospital.